Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
ACTIVE_NOT_RECRUITING
Status
Conditions
Interventions
- COMBINATION_PRODUCT: Tezepelumab
- COMBINATION_PRODUCT: Budesonide/formoterol
- COMBINATION_PRODUCT: Albuterol/budesonide (AIRSUPRA®)
- COMBINATION_PRODUCT: Mannitol
- COMBINATION_PRODUCT: Salbutamol
Sponsor
AstraZeneca
Collaborators